Bookmark and Share
BioAssay: AID 504543

Screening for Inhibitors of Bacterial Capsule Biogenesis E.coli strain UT189 with C7 control (2)

Over 100 million UTIs occur annually throughout the world, including more than 7 million cases in U.S. adolescents and adults. UTIs in younger children are associated with greater risk of morbidity and mortality than in older children and adults. Antimicrobial resistance among UPEC is on the rise, driving efforts to elucidate vulnerable targets in the molecular pathogenesis of infection. New more ..
_
   
 Tested Compounds
 Tested Compounds
All(9)
 
 
Active(2)
 
 
Inactive(7)
 
 
 Tested Substances
 Tested Substances
All(9)
 
 
Active(2)
 
 
Inactive(7)
 
 
 Related BioAssays
 Related BioAssays
AID: 504543
Data Source: Southern Research Specialized Biocontainment Screening Center (ECPhage_SecOD2)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-03-23
Hold-until Date: 2012-02-22
Modify Date: 2012-02-22

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compounds: 2
Related Experiments
Show more
AIDNameTypeComment
488970Screening for Inhibitors of Bacterial Caspule Biogenesis - SummarySummarydepositor-specified cross reference
504675Screening for Inhibitors of Bacterial Capsule Biogenesis E.coli strain UT189 with C7 control (3)Confirmatorydepositor-specified cross reference
504676Screening for Inhibitors of Bacterial Capsule Biogenesis - T7 Lysis Inhibition (3)Confirmatorydepositor-specified cross reference
504733Orcinol Secondary Screening for Inhibitors of Bacterial Capsule BiogenesisOtherdepositor-specified cross reference
504767Screening for Inhibitors of Bacterial Capsule Biogenesis - T7 Lysis Inhibition (4)Confirmatorydepositor-specified cross reference
504831Cytotoxicity screening for potential Inhibitors of Bacterial Capsule Biogenesis (3)Confirmatorydepositor-specified cross reference
588321Screening for Inhibitors of Bacterial Capsule Biogenesis E.coli strain UT189 (5).Confirmatorydepositor-specified cross reference
588322Screening for Inhibitors of Bacterial Capsule Biogenesis - T7 Lysis Inhibition (5)Confirmatorydepositor-specified cross reference
588386Screening for Inhibitors of Bacterial Capsule Biogenesis E.coli strain UT189 (6)Confirmatorydepositor-specified cross reference
588395Screening for Inhibitors of Bacterial Capsule Biogenesis E.coli strain UT189 (7)Confirmatorydepositor-specified cross reference
588399Cytotoxicity screening for potential Inhibitors of Bacterial Capsule Biogenesis (4)Confirmatorydepositor-specified cross reference
602408Confirmatory Screen for Inhibitors of Bacterial Capsule Biogenesis (2)Confirmatorydepositor-specified cross reference
602414Cytotoxicity screening for potential Inhibitors of Bacterial Capsule Biogenesis (5)Confirmatorydepositor-specified cross reference
624055Screening for Inhibitors of Bacterial Capsule Biogenesis - T7 Lysis Inhibition (6)Confirmatorydepositor-specified cross reference
624056Screening for Inhibitors of Bacterial Capsule Biogenesis - T7 Lysis Inhibition (7)Confirmatorydepositor-specified cross reference
624060Orcinol Secondary Screening for Inhibitors of Bacterial Capsule Biogenesis (2)Otherdepositor-specified cross reference
624061K5 Secondary Screening for Inhibitors of Bacterial Capsule BiogenesisOtherdepositor-specified cross reference
652019Screening for Inhibitors of Bacterial Capsule Biogenesis - T7 Lysis Inhibition (Specificity Screen) (6)Confirmatorydepositor-specified cross reference
652021Cytotoxicity screening for potential Inhibitors of Bacterial Capsule Biogenesis (4)Confirmatorydepositor-specified cross reference
488966Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule BiogenesisConfirmatorysame project related to Summary assay
493020Cytotoxicity screening for potential Inhibitors of Bacterial Capsule BiogenesisConfirmatorysame project related to Summary assay
504349Screening for Inhibitors of Bacterial Capsule Biogenesis - T7 Lysis InhibitionConfirmatorysame project related to Summary assay
504358Screening for Inhibitors of Bacterial Capsule Biogenesis E.coli strain UT189 with C7 controlConfirmatorysame project related to Summary assay
504538Screening for Inhibitors of Bacterial Capsule Biogenesis - T7 Lysis Inhibition (2)Confirmatorysame project related to Summary assay
504768Screening for Inhibitors of Bacterial Capsule Biogenesis E.coli strain UT189 with C7 control (4)Confirmatorysame project related to Summary assay
504769Cytotoxicity screening for potential Inhibitors of Bacterial Capsule Biogenesis (2)Confirmatorysame project related to Summary assay
Description:
Over 100 million UTIs occur annually throughout the world, including more than 7 million cases in U.S. adolescents and adults. UTIs in younger children are associated with greater risk of morbidity and mortality than in older children and adults. Antimicrobial resistance among UPEC is on the rise, driving efforts to elucidate vulnerable targets in the molecular pathogenesis of infection. New insights into the roles of K capsules in UPEC virulence during UTI make capsules an attractive target. Uropathogenic Escherichia coli (UPEC) produces 80% of community-acquired urinary tract infections (UTI). UPEC is also a leading cause of nosocomial UTI, the most prevalent hospital acquired infection. Dissemination of UPEC from the lower urinary tract is associated with morbidity and mortality through infection of the kidneys, bloodstream, and central nervous system. In recent years, the treatment of outpatient and inpatient UTI has been severely compromised by the rising incidence of antibiotic-resistant UPEC.

Investigators have found that encapsulation is an important UPEC virulence factor. The K1 capsule type is closely associated with pathogenic isolates; not only is it the leading type in UTI, but it also accounts for much of the extra-urinary tract complications. Animals studies of E. coli K1 sepsis demonstrated that injection of K1 capsule degrading enzyme abrogates infection. However, the enzyme treatment is immunogenic; accordingly, chemical inhibition may prove to be a superior approach.

Of the different K types, the Group 2 and Group 3 capsules are most prevalent among UPEC isolates, with K1 and K5 being leading types. Although the capsules have different compositions, they are synthesized, assembled, and exported by functionally homologous factors, leading us to hypothesize that we can develop small molecular inhibitors of K-type encapsulation that target the most medically important K types. Furthermore, the medically important infectious agents Campylobacter jejuni, Hemophilus influenzae, Neisseria meningitides, and Salmonella typhimurium among others, use these homologues in the biogenesis of their capsules. By exploiting the properties of a K-type specific phage, we performed a small scale high-throughput screen of >2,100 molecules from the NCI that uncovered several promising inhibitors of K1 and K5 encapsulation. This assay will identify a larger number of inhibitors with different mechanisms of action from which we may determine the optimal targets for capsule biogenesis inhibition and develop analogues with pharmacologically optimized properties.

Chemical modulators of K1 encapsulation might represent a new avenue to combat the catastrophic effects K1 diseases. To this end, this team has successfully developed a 1536-well high-throughput primary screen suitable for the discovery of novel capsule biogenesis inhibitors. This 96-well format confirmatory-screen for dose-response confirmation of the primary screen hits is detailed below.
Protocol
E. coli strain UT189 w/ C7 control. This screen recapitulated the primary screen in the culture tube format. Compounds were received in powder form and resuspended in DMSO to create 10 mM storage stocks . One hundred microliters of each compound was taken and diluted two-fold sequentially to 0.078 mM in PCR strip tubes to create working stocks. Compounds were kept frozen in sealed vials or PCR tubes at -20C (protected from light). Overnight cultures of UTI89 (K1) and kpsM mutant were grown in LB from a colony on a plate (from freezer stock). The cultures were then diluted 1:100 into a clean and sterile 96-well flat bottom tray (99 ml per well). Compounds were then added to each well (1 ml per well for final concentrations ranging from 100 mM to 0.78 mM (for indicated wells, DMSO only was diluted to a final concentration of 1%). Each compound concentration was tested in quadruplicate. Each plate contained controls for growth of UTI89 with and without phage as well as kpsM mutant resistant to phage lysis. On a LB plate, UTI89 and kpsM were tested for K1F phage sensitivity to confirm lysis of UTI89 by phage preparation. The plate was then sealed with tape and placed in a shaker at 37C. After incubating the plate at 37C with shaking for 1.25 hrs, an absorbance reading (OD600) of the plate was taken and indicated wells were infected with 5 microliters of K1F phage (from freshly cleared lysate). The plate was returned to the shaker and a second growth reading was taken 3 hrs post infection to determine lysis.
Comment
Inhibition of phage lysis was calculated relative to the mean of the cell control (minus phage). Data are graphed as the mean A600 at 3 hrs p.i. +/- SD of four wells normalized to the average of UTI89 + DMSO + no phage (3 hrs p.i.). Values are expressed as percentages and graphed as % Inhibition of Phage Lysis (which is equivalent to cell viability). Inhibition of phage lysis was determined at each of 9 tested concentrations ranging from 100 uM to 0.78 uM. IC50 values were calculated only for active compounds using XLFit.

Outcome: Compounds that showed inhibition of phage lysis of >= 50% at any point on the dose response curve were considered Active.

Score: In this secondary dose response screen using synthesized compounds, active compounds were scored on a scale of 81-100 based on the relative IC50 values. Compounds that were not confirmed as active in the dose response screen were given the score 0. Primary screen data is scored on a scale of 0-40, confirmatory data is ranked from 41-100.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Activity ConfirmedWas activity seen in previous tests observed with this sample?String
2IC50 ModifierString
3IC50*FloatμM
4CC50 ModifierString
5CC5050% Viability Concentration from Cytotoxicity testFloatμM
6SI ModifierString
7SISelectivity (CC50/IC50)Float
8Percent Inhibition of Phage Lysis @ 300 uM (300μM**)Float%
9Percent Inhibition of Phage Lysis @ 150 uM (150μM**)Float%
10Percent Inhibition of Phage Lysis @ 75 uM (75μM**)Float%
11Percent Inhibition of Phage Lysis @ 37.5 uM (37.5μM**)Float%
12Percent Inhibition of Phage Lysis @ 18.75 uM (18.75μM**)Float%
13Percent Inhibition of Phage Lysis @ 9.38 uM (9.38μM**)Float%
14Percent Inhibition of Phage Lysis @ 4.69 uM (4.69μM**)Float%
15Percent Inhibition of Phage Lysis @ 2.34 uM (2.34μM**)Float%
16VerificationData has been verifiedString

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1 R03 MH090791-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: